Skip to main content

Table 1 Mean changes in Multidimensional Fatigue Inventory ratings in pain responders and non-responders

From: Improvement in multiple dimensions of fatigue in patients with fibromyalgia treated with duloxetine: secondary analysis of a randomized, placebo-controlled trial

Multidimensional Fatigue Inventory

Responders

Non-responders

 

Duloxetine

(n= 140)

Placebo

(n= 103)

Duloxetine

(n= 105)

Placebo

(n= 150)

 

Mean change (SD)

Mean change (SD)

Mean change (SD)

Mean change (SD)

General Fatigue

-3.4 (3.8)

-2.8 (3.4)

-0.7 (3.3)

-0.4 (2.8)

Mental Fatigue

-3.0 (4.4)

-1.8 (3.6)

-0.9 (3.6)

-0.5 (3.2)

Physical Fatigue

-3.1 (3.9)

-2.7 (3.2)

-0.6 (2.7)

-0.3 (2.9)

Reduced Activity

-2.6 (4.0)

-1.7 (3.6)

-0.2 (3.3)

0.2 (3.4)

Reduced Motivation

-2.7 (3.3)

-1.6 (3.3)

-0.6 (3.1)

-0.4 (3.2)

  1. Pain response was defined as an at least 50% reduction from baseline in Brief Pain Inventory average pain severity. A last-observation-carried-forward analysis was conducted during the acute phase. SD, standard deviation.